-PTI Drug regulator DGCI is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drug makers, but says it remains confident of the quality standards of Indian medicines despite concerns raised by US authorities over some of Ranbaxy's products. While the company continues to assert that its drugs meet all regulatory standards, a few hospitals and pharmacies have adopted a cautious stand on use of its products. However, a majority...
More »SEARCH RESULT
Inferior drugs disturb doctors-Shuchismita Chakraborty
-The Telegraph The medical fraternity is worried over the seizure of sub-standard and fake drugs, at times lethal for patients. Police on Wednesday seized 30 boxes of suspected spurious drugs from a cart in the Gandhi Maidan area. Station House Officer of Gandhi Maidan police station Rajbindu Prasad said nobody could produce transaction bills for the consignment. The drugs seized were ofloxacin (for respiratory tract infections), oflozen (for typhoid), ossopan (calcium tablets prescribed...
More »Cancer medication as low as Rs 1,000/month on way -Malathy Iyer
-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...
More »US drug regulator detects lapses in Hospira's TN unit -Rajesh Chandramouli
-The Times of India CHENNAI: The US Food and Drug Administration (FDA) has rapped pharma giant Hospira for serious lapses in manufacturing of drugs at its Sriperumbudur unit. The US agency has warned the firm that this could result in drugs made at the plant not being allowed entry into the US. Hospira, in a regulatory filing, said it had received a warning letter from the agency . The letter followed an...
More »Indian pharma's generic challenge-DG Shah
-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...
More »